

S6 Table. Characteristics of patients with and without statin exposure before the diagnosis of breast cancer (included HER2-avaliable patients only)

	No statin (n=4,235)	Patients with statin exposure (n=626)	Total (n=4,861)	p-value
Histologic type				
IDC	3,540 (83.59)	501 (80.03)	4,041 (83.13)	0.083 ^{a)}
ILC	149 (3.52)	28 (4.47)	177 (3.64)	
Others	546 (12.89)	97 (15.50)	643 (13.23)	
Stage: T				
T0	15 (0.35)	1 (0.16)	16 (0.33)	0.098 ^{a)}
T1	1,891 (44.65)	275 (43.93)	2,166 (44.56)	
T2	1,757 (41.49)	270 (43.13)	2,027 (41.70)	
T3	237 (5.60)	24 (3.83)	261 (5.37)	
T4	75 (1.77)	6 (0.96)	81 (1.67)	
Tis	260 (6.14)	50 (7.99)	310 (6.38)	
Stage: N				
N0	2,632 (62.15)	400 (63.90)	3,032 (62.37)	0.026 ^{a)}
N1	1,029 (24.30)	141 (22.52)	1,170 (24.07)	
N2	382 (9.02)	43 (6.87)	425 (8.74)	
N3	192 (4.53)	42 (6.71)	234 (4.81)	
Stage: M				
M0	4,193 (99.01)	622 (99.36)	4,815 (99.05)	0.395 ^{a)}
M1	42 (0.99)	4 (0.64)	46 (0.95)	
ER				

Negative	1,446 (34.14)	228 (36.42)	1,674 (34.44)	0.263 ^{a)}
Positive	2,789 (65.86)	398 (63.58)	3,187 (65.56)	
PR				
Negative	2,015 (47.58)	338 (53.99)	2,353 (48.41)	0.003 ^{a)}
Positive	2,220 (52.42)	288 (46.01)	2,508 (51.59)	
HER2				
Negative	3,006 (70.98)	445 (71.09)	3,451 (70.99)	0.956 ^{a)}
Positive	1,229 (29.02)	181 (28.91)	1,410 (29.01)	
Age at diagnosis (yr)				
< 40	698 (16.48)	3 (0.48)	701 (14.42)	< 0.001 ^{a)}
≥ 40 and < 50	1,675 (39.55)	62 (9.90)	1,737 (35.73)	
≥ 50	1,862 (43.97)	561 (89.62)	2,423 (49.85)	
CCI				
Mean±SD	4.01±1.84	5.08±2.25	4.15±1.93	< 0.001 ^{c)}
Median (min-max)	4 (0-12)	5 (0-14)	4 (0-14)	

Values are presented as number (%). CCI, Charlson comorbidity index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; M, metastasis; N, node; PR, progesterone receptor; SD, standard deviation; T, tumor. ^{a)}Chi-square test, ^{b)}Fisher exact test, ^{c)}Wilcoxon rank sum test.